Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2017-12-15
Target enrollment:
Participant gender:
Summary
This study will examine the appropriate dose and side effects of dasatinib, when it is given
with the standard of care chemotherapy for children and adolescents with Acute Myeloid
Leukemia (AML).